IGC (IGC Pharma) Margin of Safety % (DCF Dividends Based): N/A (As of Jun. 29, 2026)


IGC IGC Pharma Inc IGC
29 GF Score
Price $0.26
GF Value $0.24
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is IGC Pharma Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

IGC Pharma's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.


IGC vs SER, NRSN, PVCT: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, IGC Pharma's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IGC Pharma Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IGC Pharma's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where IGC Pharma's Margin of Safety % (DCF Dividends Based) falls into.


IGC
29GF Score
IGC Pharma Inc IGC
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is IGC Pharma (IGC) Overvalued in 2026?

Based on GuruFocus' analysis, IGC Pharma stock appears to be overvalued. The current stock price of $0.26 is trading 9.6% above its estimated GF Value™ of $0.24. GuruFocus considers IGC Pharma to be Fairly Valued.

Key valuation signals for IGC:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: $0.24 vs. price of $0.26 (9.6% above fair value)
  • GF Score™: 29/100 with 6 warning signs

No single metric tells the full story. See the IGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


IGC Pharma Business Description

Other Exchanges IGS1:Germany
Address 10224 Falls Road, Potomac, MD, USA, 20854
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
29GF Score

Get the complete analysis for IGC

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.26
Price
$0.24
GF Value